These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fucosylated glycosphingolipids of human myeloid cells.
    Author: Kong RK, Barrios A, Knapp W, Macher BA.
    Journal: Arch Biochem Biophys; 1993 Feb 01; 300(2):677-83. PubMed ID: 8434948.
    Abstract:
    Our efforts to determine the carbohydrate binding specificity of two myeloid-specific monoclonal antibodies (VIM-1 and VIM-10) resulted in the purification of three fucosylated glycosphingolipids from human chronic myelogenous leukemia cells. After repeated high-performance liquid chromatographic separations, two forms of fucosylated glycosphingolipids were resolved. VIM-1 and VIM-10 were found to bind to the heptaosylceramide Gal beta 1-4 (Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer with the Le(x) (Lewis X) epitope, but not to either the hexaosylceramide Fuc alpha 1-2Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1-Cer or the octaosylceramide Fuc alpha 1-2Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer, each with the Le(y) (Lewis Y) epitope. The latter two glycosphingolipids are the first Le(y) antigens to be purified from human leukocytes and structurally characterized. Binding studies with a range of glycosphingolipids from myeloid cells and other biological sources demonstrated that VIM-1 and VIM-10 bind to Le(x) glycosphingolipids with five or more sugar residues, but not to a glycosphingolipid (III3Fuc-nLc6Cer) with an internal Le(x) trisaccharide.
    [Abstract] [Full Text] [Related] [New Search]